Navigation Links
Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
Date:6/23/2009

--Integrated human AME studies comply with recent FDA guidance for earlier testing--

PRINCETON, N.J., June 23 /PRNewswire/ -- Covance Inc. today announced its integrated radiolabeled clinical pharmacology studies in compliance with Food and Drug Administration (FDA) guidance on Metabolites in Safety Testing (MIST). Recent MIST guidance requires earlier human absorption, metabolism and excretion (AME) testing in support of Investigative New Drug/Clinical Trial Application (IND/CTA) submissions.

"Integrated human AME services are designed to help reduce the time and cost of drug development by integrating clinical pharmacology AME study conduct and data management services with bioanalytical chemistry and drug metabolism," said Robert Kochan, PhD, clinical pharmacology, Covance. "Our integrated service capabilities developed by our team of experts has made us the industry leader in integrated AME testing as we recently completed our 130th AME study."

The results of AME studies provide essential information about the disposition of a drug by direct characterization of the compound's pharmacokinetics and information related to AME characteristics. Stringent data requirements for AME studies demand experienced radiochemical and chemical analysis services to obtain definitive metabolite disposition data in humans.

Covance offers 24-hour turnaround of Good Laboratory Practices (GLP) sample radioanalysis and Good Manufacturing Practices (GMP) stability and release testing of dose formulations. With more than 130 AME studies completed, Covance's team of experts deliver integrated AME study services, including on site Authorized Nuclear Pharmacist-formulated doses; cGMP formulation testing; AME study conduct and analysis of parent compound; total radioactivity; pharmacokinetic interpretation; and metabolite profiling and identification.

Covance's clinical development services include Phase I-IV clinical trial support in more than 55 countries, including emerging markets across Asia Pacific, Central and Eastern Europe, and Latin America.

About Covance

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 9,800 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Robert Kochan

http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=89400


'/>"/>
SOURCE Covance Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
2. CoAxia, Inc. Announces $21.5M Series D Financing
3. Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs
4. Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program
5. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer
6. ThermoGenesis Announces National Institute of Health Grant
7. ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
8. Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
9. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
10. Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
11. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
Breaking Medicine Technology:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):